Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Anticipate responses to change

¹School of Nursing, Duke University, Durham, NC, USA.

Nursing Management

|November 16, 2004

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

EClinicalMedicine·2026

Same author

Correlation of BMI With Potential Barriers to Mammographic Screening: Body Image, Pain, and Perceived Risk of Breast Cancer-A Cross-Sectional Study.

Journal of medical imaging and radiation oncology·2026

Same author

Consumer perspective on breast density notification in Australia.

Ecancermedicalscience·2026

Same author

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025

Same author

Informing the management of the post-COVID condition: insights from the Western Australian experience comparing those who tested positive and negative to early COVID-19 strains.

Australian health review : a publication of the Australian Hospital Association·2024

Same author

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2024